SC 103
Alternative Names: SC103Latest Information Update: 04 Apr 2008
At a glance
- Originator Scancell
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Aug 2005 This compound is still in active development - (BIO-2005)
- 08 Sep 2003 Preclinical trials in Cancer in United Kingdom (Parenteral)